Egetis Therapeutics (Sweden) Analysis
| EGTX Stock | SEK 5.41 0.19 3.39% |
Egetis Therapeutics AB is overvalued with Real Value of 4.41 and Hype Value of 5.6. The main objective of Egetis Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Egetis Therapeutics AB is worth, separate from its market price. There are two main types of Egetis Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Egetis Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Egetis Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Egetis Therapeutics stock is traded in Sweden on Stockholm Exchange, with the market opening at 09:00:00 and closing at 17:30:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Sweden. Egetis Therapeutics is usually not traded on NationalDay, International Workers ' Day, St . John 's Day, All Saints ' Day, Christmas Eve, Christmas Day, Boxing Day, New Year 's Day, Epiphany, Good Friday, Easter Sunday, Easter Monday. Egetis Stock trading window is adjusted to Europe/Stockholm timezone.
Egetis |
Egetis Stock Analysis Notes
About 52.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.52. Some equities with similar Price to Book (P/B) outperform the market in the long run. Egetis Therapeutics recorded a loss per share of 0.7. The entity had not issued any dividends in recent years. Egetis Therapeutics AB , a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rareniche diseases with unmet medical needs in the orphan drug segment. Egetis Therapeutics AB was founded in 2006 and is based in Stockholm, Sweden. Egetis Therapeutics operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 11 people. To learn more about Egetis Therapeutics AB call the company at 46 86 79 72 10 or check out https://www.egetis.com.Egetis Therapeutics Investment Alerts
| Egetis Therapeutics had very high historical volatility over the last 90 days | |
| Egetis Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 38.24 M. Net Loss for the year was (104.54 M) with loss before overhead, payroll, taxes, and interest of (58.28 M). | |
| Egetis Therapeutics AB has accumulated about 207.41 M in cash with (130.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.26. | |
| Roughly 52.0% of the company shares are held by company insiders |
Egetis Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.51 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Egetis Therapeutics's market, we take the total number of its shares issued and multiply it by Egetis Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 27th of November, Egetis Therapeutics shows the Coefficient Of Variation of 24783.51, downside deviation of 3.28, and Mean Deviation of 2.78. Egetis Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Egetis Therapeutics Price Movement Analysis
The output start index for this execution was three with a total number of output elements of fifty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Egetis Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Egetis Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Egetis Therapeutics Outstanding Bonds
Egetis Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Egetis Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Egetis bonds can be classified according to their maturity, which is the date when Egetis Therapeutics AB has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Egetis Therapeutics Predictive Daily Indicators
Egetis Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Egetis Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Egetis Therapeutics Forecast Models
Egetis Therapeutics' time-series forecasting models are one of many Egetis Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Egetis Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Egetis Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Egetis Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Egetis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Egetis Therapeutics. By using and applying Egetis Stock analysis, traders can create a robust methodology for identifying Egetis entry and exit points for their positions.
Egetis Therapeutics AB , a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rareniche diseases with unmet medical needs in the orphan drug segment. Egetis Therapeutics AB was founded in 2006 and is based in Stockholm, Sweden. Egetis Therapeutics operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 11 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Egetis Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Sectors Now
SectorsList of equity sectors categorizing publicly traded companies based on their primary business activities |
| All Next | Launch Module |
Additional Tools for Egetis Stock Analysis
When running Egetis Therapeutics' price analysis, check to measure Egetis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Egetis Therapeutics is operating at the current time. Most of Egetis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Egetis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Egetis Therapeutics' price. Additionally, you may evaluate how the addition of Egetis Therapeutics to your portfolios can decrease your overall portfolio volatility.